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Abstract
Background:  Tuberous sclerosis complex (TSC) is an autosomal dominant disorder
characterised by the development of hamartomas in a variety of organs and tissues. The disease is
caused by mutations in either the TSC1  gene on chromosome 9q34, or the TSC2  gene on
chromosome 16p13.3. The TSC1  and  TSC2  gene products, TSC1 and TSC2, form a protein
complex that inhibits signal transduction to the downstream effectors of the mammalian target of
rapamycin (mTOR). Recently it has been shown that missense mutations to the TSC1 gene can
cause TSC.
Methods: We have used in vitro biochemical assays to investigate the effects on TSC1 function of
TSC1 missense variants submitted to the Leiden Open Variation Database.
Results: We identified specific substitutions between amino acids 50 and 190 in the N-terminal
region of TSC1 that result in reduced steady state levels of the protein and lead to increased mTOR
signalling.
Conclusion: Our results suggest that amino acid residues within the N-terminal region of TSC1
are important for TSC1 function and for maintaining the activity of the TSC1-TSC2 complex.
Background
Tuberous sclerosis complex (TSC) is an autosomal domi-
nant disorder characterised by the development of hamar-
tomas in a variety of organs and tissues, including the
brain, skin and kidneys [1,2]. Mutations in either the
TSC1 gene on chromosome 9q34 [3], or the TSC2 gene on
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chromosome 16p13.3 [4] cause TSC. In most studies, 75 -
85% of individuals with TSC have been shown to carry a
germ-line TSC1 or TSC2 mutation [5-9] and a further 5 -
10% carry TSC1 or TSC2 variants where it is not abso-
lutely clear from the genetic data whether the change is
disease-causing (a pathogenic variant), or not (a neutral
variant). To determine whether these unclassified variants
are disease-causing, the effect of the changes on protein
function can be investigated [10,11].
The TSC1 and TSC2 gene products, TSC1 and TSC2, inter-
act to form a protein complex [12]. TSC2 contains a
GTPase activating protein (GAP) domain and acts on the
rheb GTPase to inhibit rheb-GTP-dependent stimulation
of the mammalian target of rapamycin (mTOR) [13]. The
exact role of TSC1 in the TSC1-TSC2 complex is less clear,
but it appears to be required for maintaining the stability,
activity and correct intracellular localisation of the com-
plex [14]. Inactivation of the TSC1-TSC2 complex results
in activation of mTOR and phosphorylation of the mTOR
targets p70 S6 kinase (S6K), ribosomal protein S6 and 4E-
BP1 [15]. The effects of amino acid changes to TSC1 or
TSC2 on TSC1-TSC2 complex formation, on the activa-
tion of rheb GTPase activity by the complex, and on the
phosphorylation status of S6K and S6 can be determined
[10,11,16]. Pathogenic missense changes towards the N-
terminus of TSC2 prevent formation of the TSC1-TSC2
complex, while missense changes towards the C-terminus
do not prevent TSC1-TSC2 binding but disrupt the rheb-
GAP activity of TSC2 directly [10]. Pathogenic TSC1 mis-
sense changes are rare [5-9]. However, recent studies of
TSC1 missense variants identified in bladder cancers [17]
and in patients with TSC [11] have shown that TSC1
amino acid substitutions can be pathogenic, reducing
steady state levels of TSC1 and leading to increased mTOR
activity.
Here, we test 13 TSC1 variants identified during mutation
screening of individuals with TSC. Our analysis confirms
that pathogenic TSC1 missense mutations reduce steady
state levels of TSC1, and result in increased mTOR signal-
ling. Furthermore, we find that the intracellular localisa-
tion of pathogenic and neutral TSC1 variants is distinct.
The pathogenic TSC1 amino acid substitutions are clus-
tered within the conserved, hydrophobic N-terminal
region of TSC1, indicating that this region plays an impor-
tant role in TSC1 function.
Methods
Comparative analysis of TSC1 amino acid substitutions
TSC1  missense variants identified in individuals with
TSC, or suspected of having TSC, and submitted to the
LOVD TSC1 mutation database [18,19] were chosen for
analysis. To predict whether the variants were likely to be
pathogenic, the amino acid substitutions were evaluated
using the BLOSUM 62 and Grantham matrices [20,21],
and a multiple sequence alignment analysis was per-
formed using SIFT software [22,23]. Hydrophobicity plots
and secondary structure predictions were generated using
DNAMAN (Lynnon BioSoft), SABLE [24] and PSIPRED
[25] software. To determine whether the identified
changes were likely to have an effect on splicing, 3 differ-
ent splice-site prediction programs were used [26-28].
Generation of constructs and antisera
Expression constructs encoding myc-tagged TSC1 variants
were derived using the QuikChange site-directed muta-
genesis kit (Stratagene, La Jolla, CA, U.S.A.). In each case
the complete open reading frame of the mutated construct
was verified by sequence analysis. Other constructs used
in this study have been described previously [10,11]. Anti-
bodies were described previously [12] or purchased from
Cell Signaling Technology (Danvers, MA, U.S.A.), except
for a mouse monoclonal antibody against TSC2 which
was purchased from Zymed Laboratories (San Francisco,
CA, U.S.A.) and a rabbit polyclonal antibody against
ubiquitin which was purchased from DAKO (Glostrup,
Denmark).
Effects of TSC1 variants on S6K T389 phosphorylation
Immunoblot analysis of S6K T389 phosphorylation in
cells over-expressing TSC1 variants was performed as
described previously [11]. Briefly, 80% confluent HEK
293T cells in 24-well cell culture dishes were transfected
with a 4:2:1 mixture of the TSC1, TSC2 and S6K expres-
sion constructs (0.7 μg DNA total) in 50 μl Dulbecco's
modified Eagle medium (DMEM) containing 2.1 μg pol-
yethyleneimine (Polysciences, Warrington, PA, U.S.A.).
Where necessary, an empty expression vector (pcDNA3;
Invitrogen, Carlsbad, CA, U.S.A.) was added to make up
the total amount of DNA. Twenty-four hours after trans-
fection the cells were washed with cold PBS and lysed in
75 μl 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 mM NaF
and 1% Triton X100 containing protease inhibitors
(Complete, Roche Molecular Biochemicals, Woerden, The
Netherlands). After centrifugation (10 000 g, 10 minutes,
4°C), the supernatant and pellet fractions were recovered
for immunoblot analysis. The pellet fractions were resus-
pended in 100 μl 62.5 mM Tris-HCl pH 6.8, 10% glycerol,
300 mM 2-mercaptoethanol, 2% SDS and sonicated (8
μm, 15 seconds, 4°C) prior to gel electrophoresis. Sam-
ples were run on 4-12% SDS-PAGE Criterion gradient gels
(BioRad, Hercules, CA, U.S.A.) and blotted onto nitrocel-
lulose. Blots were analysed using near infra-red fluores-
cent detection on an Odyssey™ Infrared Imager (169 μm
resolution, medium quality with 0 mm focus offset) (Li-
Cor Biosciences, Lincoln, NE, U.S.A.). The integrated
intensities of the protein bands relative to the wild-type
TSC1 values were determined in at least 3 separate exper-
iments using the Odyssey™ software (default settings withBMC Medical Genetics 2009, 10:88 http://www.biomedcentral.com/1471-2350/10/88
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background correction; 3 pixel width border average
method). Signal intensities were compared as described
previously [29].
Proteosome-mediated degradation of TSC1 variants
HEK 293T cells were transfected with expression con-
structs encoding TSC2, S6K and the different TSC1 vari-
ants. Twenty-four hours after transfection the culture
medium was replaced with DMEM containing either 42
μM MG-132 (Sigma-Aldrich, St. Louis, MO, U.S.A.) or
vehicle control. After 4 hours, insulin (200 nM; Sigma-
Aldrich) or vehicle control was added to the culture
medium and, after a further 30 minute incubation, the
cells were harvested and analysed by immunoblotting, as
before.
Immunofluorescent detection of TSC1 variants
HEK 293T cells were seeded onto glass coverslips coated
with poly-L-lysine (Sigma-Aldrich), transfected with
expression constructs encoding the TSC1 variants and
processed for immunofluorescent microscopy as
described previously [12]. Fixed, permeabilised cells were
incubated with a rabbit polyclonal antibody specific for
TSC2 [12] and a mouse monoclonal antibody specific for
the TSC1 C-terminal myc epitope tag (9B11, Cell Signal-
ing Technology), followed by fluorescein isothiocyanate-
and Cy3-coupled secondary antibodies against mouse
and rabbit immunoglobulins (DAKO) respectively. Cells
were studied using a Leica DM RXA microscope and Image
Pro-Plus version 6 image analysis software.
Results
Comparative analysis of TSC1 amino acid substitutions
We selected 13 TSC1 amino acid substitutions (TSC1
c.149T>C (p.L50P), c.153A>C (p.E51D), c.182T>C
(p.L61P), c.278T>G (p.L93R), c.397G>T (p.V133F),
c.568C>T (p.R190C), c.569G>C (p.R190P), c.1001C>T
(p.S334L), c.1433A>G (p.E478G), c.1648C>G
(p.Q550E), c.1974C>G (p.D658E), c.1976C>T
(p.A659V) and c.2420T>C (p.I807T)) that were either
possible pathogenic changes, or could not be excluded as
neutral variants [18] (Table 1). In this group there was one
confirmed de novo change, TSC1 c.182T>C (p.L61P), that
was very likely to be pathogenic. In one individual with
TSC, 2 TSC1 missense changes, c.149T>C (p.L50P) and
c.2420T>C (p.I807T), were reported. To establish whether
either of these changes was responsible for TSC, or
whether the combination of both changes was required to
inactivate TSC1, we tested a L50P-I807T double variant as
well as the L50P and I807T single variants.
To predict whether the amino acid substitutions were
likely to be pathogenic, we determined the scores of the
BLOSUM 62 [20] and Grantham [21] amino acid substi-
tution matrices for all the missense variants in the LOVD
TSC1 database (Figure 1A and 1B). These scores give an
indication of the differences between amino acid pairs
based on amino acid composition, polarity and molecular
volume, as well as substitution frequencies. Both matrices
indicated that the amino acid substitutions listed in the
LOVD TSC1 database in general become more conserva-
tive towards the C-terminal of TSC1. We also performed a
SIFT analysis [23] using a multiple sequence alignment of
TSC1 derived from 14 different species (human, chimpan-
zee, maccaca, cow, dog, horse, mouse, rat, chicken, puffer-
fish, honey bee, fruitfly, mosquito and fission yeast). The
SIFT algorithm combines information from both the
chemical structure of the individual amino acids and the
evolutionary conservation of the protein to predict for
each amino acid residue which substitutions can be toler-
ated by the protein. The results of the SIFT analysis are
shown in Figure 1C and Table 1. Overall, the N-terminal
(amino acids 1 - 270) and C-terminal (amino acids 680 -
1164) regions of TSC1 did not tolerate amino acid substi-
tutions while the central region (amino acids 270 - 680)
was predicted to be more tolerant (Figure 1C). Of the 13
Table 1: Summary of the functional analysis of TSC1 missense variants from the LOVD TSC1 mutation database
Nucleotide change Exon Amino acid substitution SIFT prediction Effect on TSC1 function?
(t-test)
Conclusion
c.149T>C 4 p.L50P not tolerated yes (p = 0.03) pathogenic
c.153A>C 4 p.E51D tolerated no (p = 0.3) neutral variant
c.182T>C 4 p.L61P not tolerated yes (p = 0.002) pathogenic
c.278T>G 5 p.L93R not tolerated yes (p = 0.03) pathogenic
c.397G>T 6 p.V133F not tolerated yes (p = 0.005) pathogenic
c.569G>C 7 p.R190P not tolerated yes (p = 0.004) pathogenic
c.568C>T 7 p.R190C not tolerated no (p = 0.19) neutral variant
c.1001C>T 10 p.S334L tolerated no (p = 0.19) neutral variant
c.1433A>G 14 p.E478G tolerated no (p = 0.6) possible splice mutation
c.1648C>G 15 p.Q550E tolerated no (p = 0.9) neutral variant
c.1974C>G 15 p.D658E tolerated no (p = 0.13) neutral variant
c.1976C>T 15 p.A659V tolerated no (p = 0.1) neutral variant
c.2420T>C 19 p.I807T tolerated no (p = 0.18) neutral variantBMC Medical Genetics 2009, 10:88 http://www.biomedcentral.com/1471-2350/10/88
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substitutions selected for this study, 7 were predicted to be
tolerated and therefore unlikely to be pathogenic (Table
1). Of these, 5 were located in the central, substitution-
tolerant region of TSC1 (amino acids 270 - 680). Six sub-
stitutions were predicted not to be tolerated and therefore
likely to be pathogenic. All of these changes were located
in the substitution-intolerant N-terminal region (amino
acids 1 - 270). Finally, we investigated the effect of the
substitutions on the hydrophobicity of TSC1 (Figure 1D
and 1E). Three substitutions, p.E51D, p.Q550E and
p.D658E, had no significant effect. These were all pre-
dicted by the SIFT algorithm to be tolerated changes. Of
the remaining tolerated changes, p.S334L, p.E478G and
p.A659V increased the hydrophobicity, while the p.I807T
substitution had the opposite effect (Figure 1D). In the
group of changes not tolerated by the SIFT analysis, the
p.L50P, p.L61P, p.L93R and p.V133F substitutions
decreased the hydrophobicity while the p.R190C and
p.R190P substitutions increased the hydrophobicity (Fig-
ure 1E).
Predicted effects of amino acid substitutions on TSC1 Figure 1
Predicted effects of amino acid substitutions on TSC1. (A) Plot of BLOSUM 62 scores for substitutions in the LOVD 
TSC1 mutation database. Positive values represent conservative substitutions, negative values represent non-conservative sub-
stitutions. Substitutions investigated in this study are indicated. (B) Plot of Grantham scores for substitutions in the LOVD 
TSC1 mutation database. The higher the Grantham score, the less conservative the substitution. Substitutions investigated in 
this study are indicated. (C) SIFT analysis of TSC1. Each amino acid is represented by a box. Solid green boxes represent posi-
tions that are completely tolerant (all substitutions possible); open green boxes represent positions where 1 or 2 substitutions 
are not tolerated. Solid red boxes represent intolerant positions (no substitutions tolerated); open red boxes represent posi-
tions where 3 or fewer substitutions are tolerated. Empty boxes represent positions where between 3 and 17 substitutions are 
tolerated. The positions of substitutions tested in this study are indicated in blue. (D) Comparative hydrophobicity profile of 
wild-type TSC1 with variants predicted by SIFT analysis to be tolerated. Hydrophobicity values were calculated for each amino 
acid using DNAMAN software (default parameters). Differences in the predicted hydrophobicity per amino acid were plotted. 
Values > 0 indicate an increase in hydrophobicity of the variant relative to wild-type; values < 0 indicate a decrease. Variants 
analysed as part of this study are indicated. (E). Comparative hydrophobicity profile of wild-type TSC1 with variants predicted 
by SIFT analysis not to be tolerated.BMC Medical Genetics 2009, 10:88 http://www.biomedcentral.com/1471-2350/10/88
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Splice site prediction analysis of the TSC1  nucleotide
changes was performed using 3 independent splice site
prediction programs. Neither NetGene2 [26] nor Human
Splicing Finder [28] predicted any splicing defects for any
of the 13 changes. In contrast, NNSPLICE 0.9 [27] pre-
dicted that the TSC1 c.1433A>G (p.E478G) change would
result in the creation of an alternative splice donor site 6
nucleotides downstream of the wild-type exon 14 donor
site. Furthermore, the wild-type site was no longer recog-
nised as a splice donor site by the NNSPLICE 0.9 algo-
rithm. If this prediction is correct, the new splice donor
site created by the TSC1 c.1433A>G change would result
in the insertion of 2 extra codons (encoding amino acids
GN) between codons 479 and 480, in addition to the
p.E478G substitution.
Functional analysis of TSC1 amino acid substitutions
We characterised the effects of the 13 TSC1 single mis-
sense variants and the L50P/I807T double variant on the
activity of the TSC1-TSC2 complex. We compared the 14
variants to wild-type TSC1 and the TSC1-L117P patho-
genic variant [11]. As shown in Figure 2, the L50P, L61P,
L93R, V133F and R190P amino acid substitutions all
resulted in reduced levels of TSC1 (Figure 2A and 2B) and
increased mTOR activity, as estimated by the T389 phos-
phorylation status of S6K (Figure 2A and 2D). These sub-
stitutions all had the same effect on TSC1 as the
previously-characterised L117P substitution [11]. In each
case, the T389/S6K ratio was significantly different from
wild-type TSC1 (unpaired t-test p values all < 0.05; Table
1). We did not observe any differences between the L50P
variant and the L50P/I807T double variant. Both variants
were detected at low levels and did not inhibit S6K phos-
phorylation as effectively as wild-type TSC1.
The E51D, R190C, S334L, E478G, Q550E, D658E, A659V
and I807T variants were detected at comparable levels to
wild-type TSC1 (Figure 2A and 2B) and S6K T389 phos-
phorylation was reduced to the same levels as in the pres-
ence of wild-type TSC1 (Figure 2A and 2D). In each case,
there was no significance difference in the T389/S6K ratio
compared to wild-type TSC1 (unpaired t-test p values >
0.05; Table 1).
TSC1 variants are degraded by the proteosome
We considered two possible reasons for why the TSC1
L50P, L61P, L93R, V133F, R190P and L50P/I807T vari-
ants were detected at low levels. One possibility was that
the variants were insoluble and therefore not present in
the cell lysate fraction analysed by immunoblotting. We
analysed the insoluble post cell lysis pellet fractions, but
did not detect any of the TSC1 variants in these fractions
(data not shown).
The second possibility was that the L50P, L61P, L93R,
V133F, R190P and L50P/I807T variants were subject to
rapid turn-over and degradation. Therefore, we treated
cells expressing wild-type TSC1 or the L50P, L61P, L93R,
V133F, R190P, L50P/I807T or L117P variants with the
proteosome-inhibitor MG-132 [30]. After 4 hours treat-
ment we observed an increase in the L50P, L61P, L93R,
V133F, R190P, L50P/I807T and L117P signals when cells
were treated with MG-132 (Figure 3A).
We estimated mTOR activity in MG-132-treated cells by
measuring the T389 phosphorylation status of S6K in cells
expressing the L50P or L117P variants and treated with
MG-132 and/or insulin (Figure 3B-3D). The L50P and
L117P signals were increased relative to the TSC1 wild-
type signals in unstimulated cells treated with MG-132 as
well as in cells treated with MG-132 and stimulated with
200 nM insulin for 30 minutes (Figure 3B and 3C). In
(unstimulated and insulin stimulated) cells not treated
with MG-132, wild-type TSC1 was detected at higher lev-
els than the L50P and L117P variants, consistent with the
analysis shown in Figure 2. In untreated cells, S6K T389
phosphorylation was increased in cells expressing the
L50P and L117P variants, compared to cells expressing
wild-type TSC1, consistent with the analysis shown in Fig-
ure 2. MG-132 treatment did not affect the detected levels
of total S6K (Figure 3A), but in cells expressing the L50P
and L117P variants, S6K T389 phosphorylation was
increased compared to cells expressing wild-type TSC1, in
both insulin-stimulated and unstimulated cells (Figure 3B
and 3D).
Intracellular localisation of the TSC1 variants
Exogenous expression of the TSC1 E51D variant resulted
in the formation of large, cytoplasmic TSC1 protein aggre-
gates (Figure 4A), consistent with previous results with
wild-type TSC1 [31]. Coexpression of TSC2 resulted in a
dramatic reduction in the number of aggregates, and both
TSC2 and the TSC1 E51D variant were detected through-
out the cytoplasm (Figure 4C and 4D). We observed the
same expression pattern for the TSC1 R190C, S334L,
E478G, Q550E, D658E, A659V and I807T variants (data
not shown).
In contrast to wild-type TSC1 and the E51D, R190C,
S334L, E478G, Q550E, D658E, A659V and I807T vari-
ants, the L50P variant did not form large cytoplasmic
aggregates when over-expressed in HEK 293T cells.
Instead, the variant was expressed relatively uniformly
throughout the cytoplasm (Figure 4F). This localisation
was unaffected by coexpression of TSC2 (Figure 4H and
4I) or by MG-132 treatment (Figure 4K). The intracellular
localisation patterns of the L61P, L93R, V133F and R190P
variants were indistinguishable from the L50P variant
(data not shown).BMC Medical Genetics 2009, 10:88 http://www.biomedcentral.com/1471-2350/10/88
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Figure 2 (see legend on next page)BMC Medical Genetics 2009, 10:88 http://www.biomedcentral.com/1471-2350/10/88
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Discussion
We investigated the effects of 13 putative pathogenic
amino acid substitutions on TSC1 function. Our findings
are summarised in Table 1. The TSC1 c.149T>C (p.L50P),
c.182T>C (p.L61P), c.278T>G (p.L93R), c.397G>T
(p.V133F) and c.569G>C (p.R190P) changes resulted in
reduced levels of TSC1, a reduction in the TSC1-TSC2-
dependent inhibition of mTOR activity and a distinct
intracellular expression pattern compared to wild-type
TSC1. We conclude that these changes are pathogenic.
According to the LOVD TSC1  mutation database the
p.L61P and p.L93R substitutions are probably pathogenic
[18]. Our functional analysis supports this conclusion.
The p.L50P, p.V133F and p.R190P substitutions are clas-
sified as being of unknown pathogenicity in the database.
Our data indicates that these changes are pathogenic.
Several studies indicate that TSC1 mutations are associ-
ated with a less severe clinical presentation in TSC patients
[7-9] and further study is required to determine whether
patients with a TSC1 missense mutation follow this pat-
tern, or have a distinct phenotypic spectrum compared to
other TSC patient groups.
The c.153A>C (p.E51D), c.568C>T (p.R190C),
c.1001C>T (p.S334L), c.1648C>G (p.Q550E),
c.1974C>G (p.D658E), c.1976C>T (p.A659V) and
c.2420T>C (p.I807T) substitutions did not affect TSC1 in
our assays and were predicted to have no effect on TSC1
mRNA splicing. The LOVD TSC1 mutation database lists
the c.153A>C (p.E51D), c.568C>T (p.R190C) and
c.1001C>T (p.S334L) variants as probably not patho-
genic, and our functional analysis indicates that they are
neutral variants. Furthermore, mutation screening in
additional individuals with TSC resulted in the identifica-
tion of definite pathogenic TSC2 mutations in patients
carrying the c.153A>C (p.E51D), c.568C>T (p.R190C)
and c.1001C>T (p.S334L) substitutions, confirming the
classification of these variants as non-pathogenic (data
not shown). The LOVD TSC1 mutation database lists the
c.1648C>G (p.Q550E) and c.2420T>C (p.I807T) variants
as being of unknown pathogenicity. Our analysis indi-
cates that these variants are not pathogenic, although we
could not confirm experimentally that they do not affect
TSC1 mRNA splicing.
The c.1433A>G (E478G) substitution is listed as being of
unknown pathogenicity and did not affect TSC1 function
in our assays. However, one of three splice site prediction
programs identified a potential effect of this substitution
on splicing. We did not have access to RNA from this par-
ticular individual so we compared the activity of the pro-
tein product of the predicted splice isoform to wild-type
TSC1, the E478G variant and the L117P pathogenic vari-
ant. We did not observe any differences between the pre-
dicted TSC1 E478GinsGN variant and either wild-type
TSC1 or the E478G [see Additional Files 1 and 2]. There-
fore, we did not find any evidence that the c.1433A>G
substitution was pathogenic.
All of the amino acid substitutions that affected TSC1
function in our assays were in the N-terminal region of
TSC1 that was shown by our SIFT analysis to be relatively
intolerant of amino acid changes (amino acids 1 - 270; see
Figure 1). Two amino acid substitutions from this region,
p.E51D and p.R190C, did not affect TSC1 function in our
assays. Aspartate (E) and glutamate (D) are acidic amino
acids. The BLOSUM 62 and Grantham matrices classify
this substitution as conservative (Figure 1A and 1B) and
our SIFT analysis predicted that the p.E51D substitution
should be tolerated (Table 1). Therefore, in this case, the
experimental data were in agreement with the in silico pre-
dictions. In contrast, the p.R190C substitution was non-
conservative according to the BLOSUM 62 and Grantham
matrices and was not tolerated according to our SIFT anal-
ysis. The predictions were therefore inaccurate for this par-
ticular amino acid substitution since the functional
analysis did not reveal an effect on TSC1 function, and
genetic analysis indicated that the substitution was not
pathogenic. This result demonstrates that a conclusion
Immunoblot analysis of TSC1 variants Figure 2 (see previous page)
Immunoblot analysis of TSC1 variants. (A) Cells expressing the TSC1 variants and control cells expressing wild-type 
TSC1 and S6K only (TSC1/S6K), TSC2 and S6K only (TSC2/S6K), S6K only (S6K) or empty vector only (control) were ana-
lysed by immunoblotting. (B) Quantification of the immunoblot signals for the TSC1 variants. The integrated intensities of the 
signals for each variant, relative to wild-type TSC1, were determined in 3 independent experiments. Standard deviations are 
indicated. Signals significantly reduced compared to wild-type (unpaired t-test, p values < 0.05) are indicated with asterisks. (C) 
Quantification of the TSC2 signals. The TSC2 signals in the presence of the different TSC1 variants were not significantly differ-
ent from the signal in the presence of wild-type TSC1 (unpaired t-test, p values >0.05). (D) Inhibition of S6K T389 phosphor-
ylation in the presence of the TSC1 variants. The ratio of the S6K T389 phosphorylation signal to the total S6K signal (T389/
S6K) was determined relative to wild-type TSC1 (wild-type TSC1 T389/S6K ratio = 1). Standard deviations are indicated. Var-
iants with a significantly increased T389/S6K ratio (unpaired t-test p values < 0.05) are indicated with asterisks. (E) Quantifica-
tion of the total S6K signals. The total S6K signals in the presence of the different variants were not significantly different to 
wild-type TSC1 (unpaired t-test, p values >0.05).BMC Medical Genetics 2009, 10:88 http://www.biomedcentral.com/1471-2350/10/88
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with respect to pathogenicity based on in silico analysis
only should be made with caution.
To provide clinicians and researchers with the maximum
amount of information, gene variant databases should
move towards incorporating both in vitro and in silico data
[32]. We will add the functional and in silico results on the
variants described here to the LOVD TSC1 database as part
of the individual entries. We will include the BLOSUM 62,
Grantham and SIFT scores as well as the potential splice
effects of the different variants. However, for all apparent
missense variants, conclusions with regard to pathogenic-
ity will continue to rely on clinical, family and functional
data. As the above example shows, although in silico anal-
ysis is a valuable research tool, it is not yet reliable enough
to inform clinical decisions.
All the pathogenic TSC1 amino acid substitutions identi-
fied to date map between residues 50 and 224 (this study
and [11]). One explanation for the apparent clustering of
pathogenic amino acid substitutions to this region is that
it is critical for TSC1 function. Alternatively, these substi-
tutions may simply be less conservative than the neutral
variants we tested. Although the pathogenic substitutions
between amino acids 50 and 190 identified in this study
were not conservative, there was no clear distinction
between these changes and other neutral substitutions.
For example, as shown in Figure 1, the neutral p.R190C
variant is a non-conservative, non-tolerated substitution
that is predicted to have a large effect on TSC1 hydropho-
bicity, while the pathogenic p.R190P variant is a more
conservative substitution and has a less dramatic effect on
TSC1 hydrophobicity. Similarly, the p.V133F substitution
is more conservative than the p.R190C substitution and
has a relatively mild effect on TSC1 hydrophobicity, yet
still has a dramatic effect on TSC1 function in our assays.
In addition to the p.E51D and p.R190C substitutions, 6
other TSC1 amino acid substitutions did not affect TSC1
function in our assays. The neutral p.S334L and p.E478G
substitutions are non-conservative changes located within
the substitution-tolerant central region of TSC1 defined
by the SIFT analysis (amino acids 270 - 680; see Figure 1).
The neutral, non-conservative p.I807T substitution lies
outside this central region, but was also predicted by the
SIFT algorithm to be tolerated (Table 1). The neutral
p.Q550E, p.A659V and p.D658E substitutions are all con-
servative, tolerated changes. The results of the in silico and
functional analyses are consistent with the N-terminal of
TSC1 being a conserved, substitution-intolerant region
that has an important role in maintaining TSC1 expres-
sion and activity in the cell.
The L50P, L61P, L93R, V133F and R190P variants were
detected at lower levels compared to wild-type TSC1 and
the E51D, R190C, S334L, Q550E, D658E, A659V and
I807T variants. Inhibition of proteosome-mediated degra-
dation resulted in increased levels of the L50P and L117P
variants, indicating that the pathogenic TSC1 variants are
normally rapidly degraded by the proteosome. Interest-
ingly, increasing the levels of the TSC1 L50P and L117P
variants by inhibiting proteosome activity resulted in an
increase in mTOR activity, as estimated by the extent of
S6K T389 phosphorylation. Therefore, increased expres-
sion of the L50P and L117P variants had a dominant neg-
ative effect on mTOR signalling. One possible explanation
for this effect is that the mutant variants sequester TSC2 in
inactive TSC1-TSC2 complexes, thereby reducing the
capacity of the cells to inhibit mTOR activity. Therefore,
MG-132 treatment may help distinguish more clearly
between pathogenic and non-pathogenic TSC1 variants.
It is unlikely that this dominant negative effect is signifi-
cant in vivo in TSC patients because, as our studies indi-
cate, the L50P and L117P variants are rapidly degraded
compared to wild-type TSC1 (Figure 2A). However, it
could provide an explanation for the relative scarcity of
TSC1 missense mutations. It is possible that other mis-
sense variants are stable and do have a dominant negative
Proteosome-mediated degradation of pathogenic TSC1 variants Figure 3 (see previous page)
Proteosome-mediated degradation of pathogenic TSC1 variants. (A) Immunoblot showing levels of TSC2, wild-type 
TSC1 and pathogenic TSC1 variants in cells treated with 42 μM MG-132 for 4 hours, or left untreated. The blot was incubated 
with an antibody against ubiquitin (Ub) to show the effect of the MG-132 treatment. (B) Immunoblot showing levels of TSC2, 
wild-type TSC1 and the L50P and L117P variants, S6K and T389-phosphorylated S6K (T389) in cells treated with 42 μM MG-
132 and 200 nM insulin (+ insulin/MG-132), 42 μM MG-132 only (+ MG-132), 200 nM insulin only (+ insulin), or left untreated 
(basal). (C) Quantification of the immunoblot signals, showing MG-132-dependent inhibition of proteosome-mediated degrada-
tion of the TSC1 L50P and L117P variants. The mean integrated intensities (arbitrary units) of the signals for wild-type TSC1 
(black), and the L50P (grey) and L117P (white) variants are shown. MG-132 treatment resulted in a relative increase in the sig-
nals for the L50P and L117P variants compared to wild-type TSC1 in both insulin stimulated and unstimulated cells. (D) Quan-
tification of the immunoblot signals showing increased S6K T389 phosphorylation in MG-132 treated cells expressing the L50P 
or L117P variants. S6K T389 phosphorylation was determined as in Figure 2. (T389/S6K ratio). Compared to MG-132-treated 
cells expressing wild-type TSC1, MG-132 treatment of cells expressing the L50P and L117P variants increased the T389/S6K 
ratio.BMC Medical Genetics 2009, 10:88 http://www.biomedcentral.com/1471-2350/10/88
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effect on TSC1-TSC2 function in vivo that is incompatible
with embryonic survival.
Further study is required to explore in more detail how
amino acids close to the N-terminal (residues 50 - 224)
are important for TSC1 function. One possibility is that
they are necessary for the proposed membrane localisa-
tion of TSC1 [33]. Alternatively, they may mediate other
inter- or intramolecular interactions. Our observation that
pathogenic amino acid substitutions prevent the forma-
tion of large TSC1-containing aggregate structures sug-
gests that amino acids 50 - 224 may help mediate TSC1
homodimerisation.
Conclusion
We have analysed 13 TSC1  variants identified in TSC
patients that cause missense changes to the TSC1 protein,
and identified 5 pathogenic substitutions. Our data con-
firm that functional assays can be used to differentiate
between neutral and pathogenic variants, facilitating the
identification of pathogenic mutations in individuals
with TSC and providing insight into how specific amino
acid residues contribute to protein function.
Amino acids close to the N-terminal of TSC1 (amino acids
50 - 190) are essential for TSC1 function. Amino acid
changes to this region prevent the formation of large TSC1
aggregates and promote proteosome-mediated degrada-
tion of the protein, thereby reducing steady state levels of
TSC1 and resulting in increased signalling through
mTOR. Rapid degradation of the mutant TSC1 isoforms in
vivo most likely prevents the possible dominant negative
effects of these variants on TSC1-TSC2-dependent inhibi-
tion of mTOR signalling.
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